James Norris to Humans
This is a "connection" page, showing publications James Norris has written about Humans.
Connection Strength
0.274
-
The sphingolipid response to cancer therapy. Adv Cancer Res. 2013; 117:xiii-xvii.
Score: 0.016
-
Differential expression of epithelial and mesenchymal proteins in a panel of prostate cancer cell lines. J Urol. 2012 Aug; 188(2):632-8.
Score: 0.016
-
Acid ceramidase upregulation in prostate cancer: role in tumor development and implications for therapy. Expert Opin Ther Targets. 2009 Dec; 13(12):1449-58.
Score: 0.013
-
Acid ceramidase inhibition: a novel target for cancer therapy. Front Biosci. 2008 Jan 01; 13:2293-8.
Score: 0.012
-
Lysosomotropic acid ceramidase inhibitor induces apoptosis in prostate cancer cells. Cancer Chemother Pharmacol. 2008 Feb; 61(2):231-42.
Score: 0.011
-
Role of acid ceramidase in resistance to FasL: therapeutic approaches based on acid ceramidase inhibitors and FasL gene therapy. Mol Ther. 2007 Jul; 15(7):1259-63.
Score: 0.011
-
Involvement of sphingolipids in apoptin-induced cell killing. Mol Ther. 2006 Nov; 14(5):627-36.
Score: 0.011
-
New insights on the use of desipramine as an inhibitor for acid ceramidase. FEBS Lett. 2006 Aug 21; 580(19):4751-6.
Score: 0.011
-
Modulation of ceramide metabolism enhances viral protein apoptin's cytotoxicity in prostate cancer. Mol Ther. 2006 Nov; 14(5):637-46.
Score: 0.011
-
Combined therapeutic use of AdGFPFasL and small molecule inhibitors of ceramide metabolism in prostate and head and neck cancers: a status report. Cancer Gene Ther. 2006 Dec; 13(12):1045-51.
Score: 0.010
-
The present and future for gene and viral therapy of directly accessible prostate and squamous cell cancers of the head and neck. Future Oncol. 2005 Feb; 1(1):115-23.
Score: 0.009
-
In vitro efficacy of Fas ligand gene therapy for the treatment of bladder cancer. Cancer Gene Ther. 2005 Jan; 12(1):12-8.
Score: 0.009
-
Quantification and characterization of the bystander effect in prostate cancer cells following adenovirus-mediated FasL expression. Cancer Gene Ther. 2003 Apr; 10(4):330-9.
Score: 0.008
-
Resistance of prostate cancer cells to soluble TNF-related apoptosis-inducing ligand (TRAIL/Apo2L) can be overcome by doxorubicin or adenoviral delivery of full-length TRAIL. Cancer Gene Ther. 2002 Feb; 9(2):164-72.
Score: 0.008
-
The use of Fas Ligand, TRAIL and Bax in gene therapy of prostate cancer. Curr Gene Ther. 2001 May; 1(1):123-36.
Score: 0.007
-
Inhibition of acid ceramidase regulates MHC class II antigen presentation and suppression of autoimmune arthritis. Cytokine. 2020 11; 135:155219.
Score: 0.007
-
Tamoxifen is a candidate first-in-class inhibitor of acid ceramidase that reduces amitotic division in polyploid giant cancer cells-Unrecognized players in tumorigenesis. Cancer Med. 2020 05; 9(9):3142-3152.
Score: 0.007
-
Genetic and pharmacological inhibition of acid ceramidase prevents asymmetric cell division by neosis. J Lipid Res. 2019 07; 60(7):1225-1235.
Score: 0.006
-
Interdiction of Sphingolipid Metabolism Revisited: Focus on Prostate Cancer. Adv Cancer Res. 2018; 140:265-293.
Score: 0.006
-
Blocking Myristoylation of Src Inhibits Its Kinase Activity and Suppresses Prostate Cancer Progression. Cancer Res. 2017 12 15; 77(24):6950-6962.
Score: 0.006
-
Acid Ceramidase Deficiency is characterized by a unique plasma cytokine and ceramide profile that is altered by therapy. Biochim Biophys Acta Mol Basis Dis. 2017 02; 1863(2):386-394.
Score: 0.005
-
Tissue biomarkers of drug efficacy: case studies using a MALDI-MSI workflow. Bioanalysis. 2015; 7(20):2611-9.
Score: 0.005
-
Acid ceramidase promotes nuclear export of PTEN through sphingosine 1-phosphate mediated Akt signaling. PLoS One. 2013; 8(10):e76593.
Score: 0.004
-
Radiation-induced acid ceramidase confers prostate cancer resistance and tumor relapse. J Clin Invest. 2013 Oct; 123(10):4344-58.
Score: 0.004
-
Interdiction of sphingolipid metabolism to improve standard cancer therapies. Adv Cancer Res. 2013; 117:1-36.
Score: 0.004
-
Efficient growth suppression and apoptosis in human laryngeal carcinoma cell line HEP-2 induced by an adeno-associated virus expressing human FAS ligand. Head Neck. 2012 Nov; 34(11):1628-33.
Score: 0.004
-
Role of CXC chemokine ligand 13 in oral squamous cell carcinoma associated osteolysis in athymic mice. Int J Cancer. 2010 May 15; 126(10):2319-29.
Score: 0.003
-
Targeting sphingolipid metabolism in head and neck cancer: rational therapeutic potentials. Expert Opin Ther Targets. 2010 May; 14(5):529-39.
Score: 0.003
-
Ceramide plays a prominent role in MDA-7/IL-24-induced cancer-specific apoptosis. J Cell Physiol. 2010 Mar; 222(3):546-55.
Score: 0.003
-
A novel function of CXCL13 to stimulate RANK ligand expression in oral squamous cell carcinoma cells. Mol Cancer Res. 2009 Aug; 7(8):1399-407.
Score: 0.003
-
Acid ceramidase upregulation in prostate cancer cells confers resistance to radiation: AC inhibition, a potential radiosensitizer. Mol Ther. 2009 Mar; 17(3):430-8.
Score: 0.003
-
Molecular targeting of acid ceramidase: implications to cancer therapy. Curr Drug Targets. 2008 Aug; 9(8):653-61.
Score: 0.003
-
Tissue-specific shRNA delivery: a novel approach for gene therapy in cancer. Connect Tissue Res. 2008; 49(3):265-9.
Score: 0.003
-
Specific isoforms of p73 control the induction of cell death induced by the viral proteins, E1A or apoptin. Cell Cycle. 2008 Jan 15; 7(2):205-15.
Score: 0.003
-
Novel analogs of D-e-MAPP and B13. Part 1: synthesis and evaluation as potential anticancer agents. Bioorg Med Chem. 2008 Jan 15; 16(2):1015-31.
Score: 0.003
-
Novel analogs of D-e-MAPP and B13. Part 2: signature effects on bioactive sphingolipids. Bioorg Med Chem. 2008 Jan 15; 16(2):1032-45.
Score: 0.003
-
Clinical relevance of ceramide metabolism in the pathogenesis of human head and neck squamous cell carcinoma (HNSCC): attenuation of C(18)-ceramide in HNSCC tumors correlates with lymphovascular invasion and nodal metastasis. Cancer Lett. 2007 Oct 18; 256(1):101-11.
Score: 0.003
-
The functional effects of acid ceramidase overexpression in prostate cancer progression and resistance to chemotherapy. Cancer Biol Ther. 2007 Sep; 6(9):1455-60.
Score: 0.003
-
Recent advances and current challenges in tumor immunology and immunotherapy. Mol Ther. 2007 Jun; 15(6):1065-71.
Score: 0.003
-
The effect of dexamethasone on human mucin 1 expression and antibody-dependent complement sensitivity in a prostate cancer cell line in vitro and in vivo. Immunology. 2004 Mar; 111(3):291-7.
Score: 0.002
-
Enhanced apoptosis of glioma cell lines is achieved by co-delivering FasL-GFP and TRAIL with a complex Ad5 vector. Cancer Gene Ther. 2003 Nov; 10(11):814-22.
Score: 0.002
-
CD95 rapidly clusters in cells of diverse origins. Cancer Biol Ther. 2003 Jul-Aug; 2(4):392-5.
Score: 0.002
-
Development of a thermally regulated broad-spectrum promoter system for use in pathogenic gram-positive species. Appl Environ Microbiol. 2003 Jun; 69(6):3385-92.
Score: 0.002
-
A recombinant adenovirus expressing wild-type Bax induces apoptosis in prostate cancer cells independently of their Bcl-2 status and androgen sensitivity. Cancer Biol Ther. 2002 Mar-Apr; 1(2):163-7.
Score: 0.002
-
Construction, purification and characterization of adenovirus vectors expressing apoptosis-inducing transgenes. Methods Enzymol. 2002; 346:529-47.
Score: 0.002